Medipost announced Wednesday that it acquired patents in six European countries based on its core technology of Alzheimer's disease treatment.

The patent relates to a pharmaceutical composition for treating neuropathy using “Cell Adhesion Molecule (ICAM) -1,” a protein involved in adhesion and migration of inflammatory cells, it said

Medipost has acquired six patents in Europe for the treatment of neurological diseases.

The name of the patent is “the use of ICAM-1 for the prevention or treatment of neurological diseases,” and Medipost acquired it in the U.K., Germany, France, Italy, Spain, and Switzerland at the same time.

ICAM-1 can be secreted when a cord blood-derived stem cell is administered to a patient who has Alzheimer's disease, and it functions to induce the degradation of amyloid beta plaque, which is known as a causative agent of dementia.

"The patented technology is used in the most important process in the treatment of dementia, and it is also applied to Neurostem, a drug for Alzheimer's,” a company official said.

Medipost _{메디포스트} (CEO: Yang Yoon-sun_양윤선) has already acquired patents for the treatment of neurological diseases using ICAM-1 in Korea, U.S. Canada, Australia, China, and Japan.

connie@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>